Biomedican inc
Producing medical-grade cannabis more efficiently
Last Funded October 2021
$220,467
raised from 163 investors
Pitch Video
Investor Panel
Highlights
1
Medical-use, non-GMO cannabinoids for 70-90% less than current, wholesale prices
2
Costs less than $1/gram per cannabinoid using 90% less resources; 4 patents pending
3
70+ press mentions; Forbes, Bloomberg, Nasdaq, Reuters, Maxim, Rolling Stones
4
Partnered with Institute of Genetics Moscow, Demark Technical University, Imperial College UK
Our Team
CEO / Chief Scientist
Max is a medical, life sciences, computer sciences expert who received numerous patents, grants, and professional honors. He co-invented many patented genetic modifications and co-founded several biotech startups.
We believe that biosynthesis will shape the future and significantly influence the production of food, supplements, medical drugs, and other valuable organic compounds. We have identified rare cannabinoids as the starting point due to the high demand and limited availability. However, this is just the beginning, and we
President
Dennis O'Neill has over 25 years of experience as an Investment Banker. He raised over 2 billion dollars in capital for early-stage companies.
Difeng Gao, Ph.D.Lead Scientist
Difeng is an accomplished scientist with 10+ years of molecular biology experience, including 6 years of experience with Yarrowia Lipolytica, CRISPR, and simultaneous integration of multiple genes.
Pitch
*A max of $1.07M will be raised through Wefunder